StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $0.60 | $0.58 | -3.03% | 0.1M |
| 05-14 | $0.57 | $0.55 | -3.51% | 0.1M |
| 05-15 | $0.57 | $0.54 | -4.98% | 0.0M |
| 05-18 | $0.54 | $0.54 | -0.74% | 0.0M |
| 05-19 | $0.51 | $0.54 | +5.55% | 0.0M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $7.00K | $32.00K | $25.00K | $7.00K |
Operating Income | $-2.29M | $-4.28M | $-3.11M | $-2.17M |
Net Income | $-2.29M | $-11.84M | $-17.08M | $-15.61M |
EPS (Diluted) | $-0.02 | $-0.38 | $-1.41 | $-1.29 |
Total Assets | $17.09M | $17.41M | $18.21M | $19.06M |
Total Liabilities | $2.38M | $1.85M | $27.06M | $26.44M |
Cash & Equivalents | $20.00K | $3.00K | $12.00K | $624.00K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 107.82M | 104.62M | 12.19M | 12.19M |
No sell-side coverage available for IBO.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.